中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
14期
10-12
,共3页
肝炎%乙型%慢性%肝纤维化%脂肪肝%阿德福韦酯
肝炎%乙型%慢性%肝纖維化%脂肪肝%阿德福韋酯
간염%을형%만성%간섬유화%지방간%아덕복위지
Hepatitis%Hepatitis B%Chronic%Liver fibrosis%Fatty liver%Adefovir Dipivoxil
目的：探讨慢性乙型肝炎（CHB）合并非酒精性脂肪性肝病（NAFLD）对阿德福韦酯抗病毒疗效及对肝纤维化的影响。方法：194例CHB患者分为合并NAFLD组（A组，73例）和未合并NAFLD组（B组，121例），均给予阿德福韦酯（10 mg/d，1次/d）治疗52周。观察两组治疗前后肝功能、病毒学指标及肝纤维化指标的变化。结果：治疗后两组血清AST、ALT指标均显著下降，且B组下降幅度高于A组，差异有统计学意义（P<0.05）；B组HBeAg阴转率、HBeAg转换率和HBV-DNA转阴率显著高于A组，差异有统计学意义（P<0.05）；两组HA、LN、PCⅢ、CIV水平均较治疗前显著下降，且B组下降幅度高于A组，差异有统计学意义（P<0.05）。结论：合并NAFLD影响CHB患者肝功能恢复和肝纤维化进展，也降低阿德福韦酯抗病毒治疗的应答效应。
目的：探討慢性乙型肝炎（CHB）閤併非酒精性脂肪性肝病（NAFLD）對阿德福韋酯抗病毒療效及對肝纖維化的影響。方法：194例CHB患者分為閤併NAFLD組（A組，73例）和未閤併NAFLD組（B組，121例），均給予阿德福韋酯（10 mg/d，1次/d）治療52週。觀察兩組治療前後肝功能、病毒學指標及肝纖維化指標的變化。結果：治療後兩組血清AST、ALT指標均顯著下降，且B組下降幅度高于A組，差異有統計學意義（P<0.05）；B組HBeAg陰轉率、HBeAg轉換率和HBV-DNA轉陰率顯著高于A組，差異有統計學意義（P<0.05）；兩組HA、LN、PCⅢ、CIV水平均較治療前顯著下降，且B組下降幅度高于A組，差異有統計學意義（P<0.05）。結論：閤併NAFLD影響CHB患者肝功能恢複和肝纖維化進展，也降低阿德福韋酯抗病毒治療的應答效應。
목적：탐토만성을형간염（CHB）합병비주정성지방성간병（NAFLD）대아덕복위지항병독료효급대간섬유화적영향。방법：194례CHB환자분위합병NAFLD조（A조，73례）화미합병NAFLD조（B조，121례），균급여아덕복위지（10 mg/d，1차/d）치료52주。관찰량조치료전후간공능、병독학지표급간섬유화지표적변화。결과：치료후량조혈청AST、ALT지표균현저하강，차B조하강폭도고우A조，차이유통계학의의（P<0.05）；B조HBeAg음전솔、HBeAg전환솔화HBV-DNA전음솔현저고우A조，차이유통계학의의（P<0.05）；량조HA、LN、PCⅢ、CIV수평균교치료전현저하강，차B조하강폭도고우A조，차이유통계학의의（P<0.05）。결론：합병NAFLD영향CHB환자간공능회복화간섬유화진전，야강저아덕복위지항병독치료적응답효응。
Objective:To explore the effect on antiviral efficacy of Adefovir Dipivoxil and liver fibrosis in patients with chronic hepatitis B(CHB)by nonalcoholic fatty liver disease(NAFLD). Method:194 cases of CHB were divided into NAFLD group(group A,73 cases)and without NAFLD group(group B,121 cases),all were treated with Adefovir Dipivoxil(10 mg/d,1/d)for 52 weeks. The changes of liver function,HBV markers and liver fibrosis indexes before and after treatment were observed. Result:After treatment,the serum AST,ALT in the two groups were significantly decreased,and the decreased extent in the group B was higher than that in the group A(P<0.05);the HBeAg negative conversion rate,HBeAg conversion rate and HBV-DNA negative rate in the group B were significantly higher than that in the group A,the difference were statistically significant(P<0.05);the HA,LN,PCⅢ,CIV levels of two groups were significantly lower than before treatment,and the decreased extent in the group B was higher than that of the group A, the difference were statistically significant(P<0.05). Conclusion:NAFLD has effects on the progress of liver function recovery and hepatic fibrosis in patients with CHB,and it also reduce the antiviral efficacy of Adefovir Dipivoxil.
